PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
CORT vs. LNTH
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between CORT and LNTH is 0.28, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

CORT vs. LNTH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Corcept Therapeutics Incorporated (CORT) and Lantheus Holdings, Inc. (LNTH). The values are adjusted to include any dividend payments, if applicable.

-40.00%-20.00%0.00%20.00%40.00%60.00%80.00%AugustSeptemberOctoberNovemberDecember2025
54.95%
-21.71%
CORT
LNTH

Key characteristics

Sharpe Ratio

CORT:

2.67

LNTH:

1.04

Sortino Ratio

CORT:

3.25

LNTH:

2.06

Omega Ratio

CORT:

1.39

LNTH:

1.29

Calmar Ratio

CORT:

3.20

LNTH:

1.29

Martin Ratio

CORT:

14.99

LNTH:

4.15

Ulcer Index

CORT:

8.02%

LNTH:

15.16%

Daily Std Dev

CORT:

45.18%

LNTH:

60.88%

Max Drawdown

CORT:

-94.28%

LNTH:

-78.62%

Current Drawdown

CORT:

-15.10%

LNTH:

-25.08%

Fundamentals

Market Cap

CORT:

$5.41B

LNTH:

$6.44B

EPS

CORT:

$1.26

LNTH:

$6.02

PE Ratio

CORT:

41.00

LNTH:

15.39

PEG Ratio

CORT:

0.61

LNTH:

0.61

Total Revenue (TTM)

CORT:

$493.15M

LNTH:

$1.14B

Gross Profit (TTM)

CORT:

$485.22M

LNTH:

$749.68M

EBITDA (TTM)

CORT:

$111.81M

LNTH:

$493.72M

Returns By Period

In the year-to-date period, CORT achieves a 2.52% return, which is significantly lower than LNTH's 3.53% return.


CORT

YTD

2.52%

1M

-6.75%

6M

54.95%

1Y

122.67%

5Y*

31.64%

10Y*

32.90%

LNTH

YTD

3.53%

1M

-0.43%

6M

-21.71%

1Y

64.69%

5Y*

37.65%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

CORT vs. LNTH — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CORT
The Risk-Adjusted Performance Rank of CORT is 9595
Overall Rank
The Sharpe Ratio Rank of CORT is 9797
Sharpe Ratio Rank
The Sortino Ratio Rank of CORT is 9494
Sortino Ratio Rank
The Omega Ratio Rank of CORT is 9292
Omega Ratio Rank
The Calmar Ratio Rank of CORT is 9696
Calmar Ratio Rank
The Martin Ratio Rank of CORT is 9696
Martin Ratio Rank

LNTH
The Risk-Adjusted Performance Rank of LNTH is 8383
Overall Rank
The Sharpe Ratio Rank of LNTH is 8282
Sharpe Ratio Rank
The Sortino Ratio Rank of LNTH is 8383
Sortino Ratio Rank
The Omega Ratio Rank of LNTH is 8484
Omega Ratio Rank
The Calmar Ratio Rank of LNTH is 8585
Calmar Ratio Rank
The Martin Ratio Rank of LNTH is 8080
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

CORT vs. LNTH - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Corcept Therapeutics Incorporated (CORT) and Lantheus Holdings, Inc. (LNTH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for CORT, currently valued at 2.67, compared to the broader market-2.000.002.002.671.04
The chart of Sortino ratio for CORT, currently valued at 3.25, compared to the broader market-4.00-2.000.002.004.003.252.06
The chart of Omega ratio for CORT, currently valued at 1.39, compared to the broader market0.501.001.502.001.391.29
The chart of Calmar ratio for CORT, currently valued at 3.20, compared to the broader market0.002.004.006.003.201.29
The chart of Martin ratio for CORT, currently valued at 14.99, compared to the broader market0.0010.0020.0014.994.15
CORT
LNTH

The current CORT Sharpe Ratio is 2.67, which is higher than the LNTH Sharpe Ratio of 1.04. The chart below compares the historical Sharpe Ratios of CORT and LNTH, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.000.501.001.502.002.50AugustSeptemberOctoberNovemberDecember2025
2.67
1.04
CORT
LNTH

Dividends

CORT vs. LNTH - Dividend Comparison

Neither CORT nor LNTH has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

CORT vs. LNTH - Drawdown Comparison

The maximum CORT drawdown since its inception was -94.28%, which is greater than LNTH's maximum drawdown of -78.62%. Use the drawdown chart below to compare losses from any high point for CORT and LNTH. For additional features, visit the drawdowns tool.


-40.00%-30.00%-20.00%-10.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-15.10%
-25.08%
CORT
LNTH

Volatility

CORT vs. LNTH - Volatility Comparison

Corcept Therapeutics Incorporated (CORT) has a higher volatility of 11.39% compared to Lantheus Holdings, Inc. (LNTH) at 9.23%. This indicates that CORT's price experiences larger fluctuations and is considered to be riskier than LNTH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%25.00%30.00%35.00%40.00%AugustSeptemberOctoberNovemberDecember2025
11.39%
9.23%
CORT
LNTH

Financials

CORT vs. LNTH - Financials Comparison

This section allows you to compare key financial metrics between Corcept Therapeutics Incorporated and Lantheus Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab